The SARS-CoV-2 Lambda variant and its neutralisation efficiency following vaccination with Comirnaty, Israel, April to June 2021

The SARS-CoV-2 Lambda (Pango lineage designation C.37) variant of interest, initially identified in Peru, has spread to additional countries. First detected in Israel in April 2021 following importations from Argentina and several European countries, the Lambda variant infected 18 individuals belong...

Descripción completa

Detalles Bibliográficos
Autores principales: Zuckerman, Neta, Nemet, Ital, Kliker, Limor, Atari, Nofar, Lustig, Yaniv, Bucris, Efrat, Bar Ilan, Dana, Geva, Miranda, Sorek-Abramovich, Reut, Weiner, Chen, Rainy, Nir, Bar-Chaim, Adina, Benveniste-Levkovitz, Patricia, Abu Hamed, Ramzia, Regev-Yochay, Gili, Hevkin, Ofra, Mor, Orna, Alroy-Preis, Sharon, Mendelson, Ella, Mandelboim, Michal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2021
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646983/
https://www.ncbi.nlm.nih.gov/pubmed/34763751
http://dx.doi.org/10.2807/1560-7917.ES.2021.26.45.2100974
Descripción
Sumario:The SARS-CoV-2 Lambda (Pango lineage designation C.37) variant of interest, initially identified in Peru, has spread to additional countries. First detected in Israel in April 2021 following importations from Argentina and several European countries, the Lambda variant infected 18 individuals belonging to two main transmission chains without further spread. Micro-neutralisation assays following Comirnaty (BNT162b2 mRNA, BioNTech-Pfizer) vaccination demonstrated a significant 1.6-fold reduction in neutralising titres compared with the wild type virus, suggesting increased susceptibility of vaccinated individuals to infection.

Ejemplares similares